# US Clinical Laboratory Test Market

> US Clinical Laboratory Test Market Research Report: Size, Share, Trend Analysis By Types of Laboratory (Hospital-based, Central/Independent, Physician Office Laboratory, Others) and By Types of Test (CBC and Routine Blood Test, Anatomic Pathology, Molecular Test, Immunology Test, Drug Test, Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 15.8%
- **2024:** $ 1.21 Billion
- **2025:** $ 1.4 Billion
- **2035:** $ 6.06 Billion
- **Key Players:** Quest Diagnostics (US), Laboratory Corporation of America (US), Mayo Clinic Laboratories (US), BioReference Laboratories (US), ARUP Laboratories (US), Sonic Healthcare (AU), Genomic Health (US), Exact Sciences (US), Thermo Fisher Scientific (US)

**Report ID:** MRFR/MED/11268-CR · **Pages:** 100 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** January 29, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-clinical-laboratory-test-market-12793

---

## Market Summary

## **US Clinical Laboratory Test Market Overview**

As per MRFR analysis, the US Clinical Laboratory Test Market Size was estimated at 8.3 (USD Billion) in 2023. The US Clinical Laboratory Test Market Industry is expected to grow from 9.56 (USD Billion) in 2024 to 19.3 (USD Billion) by 2035. The US Clinical Laboratory Test Market CAGR (growth rate) is expected to be around 6.6% during the forecast period (2025 - 2035).

### **Key US Clinical Laboratory Test Market Trends Highlighted**

Currently, the US Clinical Laboratory Test Market is influenced by a number of significant market drivers. The increasing emphasis on **preventive healthcare** is a significant factor contributing to the increased demand for routine and diagnostic tests. The necessity for consistent testing to effectively manage health is also driven by the expansion of geriatric populations in the United States and a rise in chronic diseases.

Additionally, the integration of sophisticated technologies, including molecular diagnostics and automation, in laboratories improves the precision and efficiency of testing, which is advantageous to both healthcare providers and patients. The increasing popularity of personalized medication presents an opportunity to investigate opportunities in the United States market.

This method necessitates sophisticated laboratory tests to inform therapy decisions and customizes treatments according to the unique characteristics of each patient. The movement toward value-based healthcare is motivating laboratories to deliver more precise and rapid test results, necessitating that they adjust to innovative methodologies and emergent technologies.

In addition, the expansion of **telehealth** presents opportunities for remote testing services, which facilitate access to laboratory tests from the comfort of one's home. This is particularly beneficial in underserved populations.

The utilization of **point-of-care testing** (POCT) has made substantial strides in recent years, providing immediate results in a variety of contexts, including medical offices and clinics. This convenience is designed to meet the requirements of patients who require prompt diagnoses.

Furthermore, the clinical laboratory landscape has been transformed by the increasing emphasis on mental health, which has increased the testing of conditions such as anxiety and depression. It is also important to note the trend of regulatory changes, as the US government is consistently updating guidelines that may affect laboratory operations and testing protocols. This promotes the maintenance of compliance and agility in laboratories.

## **US Clinical Laboratory Test Market Drivers**

### **Rising Prevalence of Chronic Diseases**

The United States is experiencing a significant increase in chronic diseases, which is a major driver for the US Clinical Laboratory Test Market Industry. According to the Centers for Disease Control and Prevention (CDC), nearly 6 in 10 adults in the US live with at least one chronic disease, such as diabetes, heart disease, or cancer. This growing patient population necessitates regular laboratory testing for diagnosis and management.

The American Cancer Society reports that over 1.9 million new cancer cases were expected in the US in 2021 alone, which highlights the critical need for clinical laboratory tests to monitor and treat these patients effectively. Established organizations like Quest Diagnostics and LabCorp are significant players in this space, providing an extensive range of laboratory tests that cater to the needs of patients suffering from chronic conditions. As chronic diseases continue to rise, the demand for clinical laboratory services is projected to increase, driving market growth.

### **Technological Advancements in Diagnostic Testing**

Innovation in diagnostic testing technologies is another key factor contributing to the growth of the US Clinical Laboratory Test Market Industry. The introduction of advanced techniques such as Next-Generation Sequencing (NGS) and Liquid Biopsy has transformed the landscape of laboratory diagnostics. The Clinical Laboratory Improvement Amendments (CLIA) permit laboratories in the US to perform a wide variety of tests, which establishes a competitive environment that encourages technological improvements.

Companies like Illumina and Roche are at the forefront of these innovations, offering state-of-the-art solutions that enhance the accuracy and efficiency of laboratory testing. As the healthcare system increasingly adopts these technologies, it is expected to boost the demand for clinical laboratory services significantly.

### **Increased Health Awareness and Preventive Healthcare**

There has been a significant rise in health awareness among the US population, leading to an increase in preventive healthcare practices. According to the National Center for Health Statistics, about 84% of adults in the US reported having at least one preventive healthcare visit in recent years, driven by efforts to catch diseases early. This trend influences the US Clinical Laboratory Test Market Industry positively as more individuals seek laboratory tests for screening purposes.

Organizations such as the United States Preventive Services Task Force (USPSTF) advocate for regular screenings, including blood tests and cancer screenings, which spur demand for laboratory services. Furthermore, the Affordable Care Act has promoted preventive services, covering many laboratory tests, thereby encouraging more Americans to utilize these essential diagnostic tools.

## **US Clinical Laboratory Test Market Segment Insights**

### **Clinical Laboratory Test Market Type of Laboratory Insights**

The Type of Laboratory segment plays a crucial role in shaping the dynamics of the US Clinical Laboratory Test Market, reflecting a diverse landscape that caters to the various healthcare needs of the population. The market is classified into different types of laboratories, each serving distinct functions and patient demographics. Hospital-based laboratories are fundamental as they provide a wide range of diagnostic testing to inpatients and outpatients, facilitating critical decision-making in immediate care settings.

These laboratories often operate with advanced technology and resources, supporting a large volume of tests that are integral for patient management within the hospital environment. In contrast, Central or Independent laboratories are characterized by their ability to handle higher throughput of tests and diverse test menus, often specializing in specific types of diagnostics that may not be available in smaller or hospital-based setups.

This segment supports an array of clinical and research collaborations, thereby enhancing the availability of sophisticated testing solutions that are instrumental in complex cases. Additionally, Physician Office Laboratories (POL) are gaining traction due to their capacity to deliver quick test results, which enhances the patient experience by enabling immediate clinical decisions. They simplify the diagnostic process for both physicians and patients, thus bridging gaps in care delivery.

Each type of laboratory is essential to the overall efficiency of healthcare services, with their varying capabilities catering to different aspects of patient care. The Other laboratories, which include specialty and research-focused entities, contribute unique insights and expertise to the market, driving innovation and laboratory-developed tests. Collectively, these laboratory types address the growing demand for laboratory testing, which is spurred by factors such as the increased prevalence of chronic diseases, advancements in technology, and a stronger push for preventive healthcare measures.

Moreover, evolving regulations and the need for high-quality standards across the laboratory ecosystem present both challenges and opportunities for market growth. Overall, the diversity in the Type of Laboratory segment underscores its significance in advancing diagnostic capabilities within the healthcare infrastructure of the United States.

Source Primary Research, Secondary Research, MRFR Database and Analyst Review

### **Clinical Laboratory Test Market Type of Test Insights**

The US [Clinical Laboratory Test Market](../../../reports/clinical-laboratory-test-market-1649), particularly focusing on the Type of Test segmentation, showcases a diverse array of testing methodologies essential for disease diagnosis and management. Among these, CBC and Routine Blood Tests are foundational, often serving as the first line of investigation in clinical evaluations. Anatomic Pathology plays a critical role in cancer diagnosis and disease characterization, contributing significantly to patient treatment plans.

Meanwhile, Molecular Tests are gaining traction as they allow for precise identification of genetic diseases and pathogens, driving advancements in **personalized medicine**. Immunology Tests are crucial for assessing immune response and helping diagnose conditions like autoimmune disorders and allergies. Drug Tests are increasingly prevalent due to rising concerns over substance abuse and the need for compliance monitoring in various industries.

Other emerging tests complement these traditional approaches, expanding the market's capabilities. The US Clinical Laboratory Test Market data indicates that evolving healthcare needs and technologies are shaping these segments, highlighting opportunities for innovation and growth. Market growth is also supported by increasing health awareness, an aging population, and a rising prevalence of chronic diseases across the United States. These dynamics contribute to a robust industry landscape, making the Type of Test segment vital for healthcare professionals and providers.

## **US Clinical Laboratory Test Market Key Players and Competitive Insights**

The US Clinical Laboratory Test Market is characterized by a diverse range of players that compete vigorously to provide advanced diagnostic solutions. Market competition is shaped by factors such as technological innovation, regulatory compliance, reimbursement policies, and evolving healthcare needs. In recent years, there has been a surge in the demand for personalized medicine and preventive care, which has prompted clinical laboratories to adapt their offerings and expand services.

Strong competition is noted across various segments of the market, including molecular diagnostics, clinical chemistry, immunoassay, and hematology, with each segment undergoing continuous enhancement through research and collaborations. Companies are striving to leverage cutting-edge technologies, such as automation and artificial intelligence, to enhance diagnostic accuracy and operational efficiencies, thereby positioning themselves favorably in this dynamic market.

Exact Sciences stands out in the US Clinical Laboratory Test Market, particularly known for its focus on early cancer detection and prevention. The company has established itself as a pivotal player through its innovative testing methodologies and a strong emphasis on research and development. With a proprietary portfolio that includes non-invasive tests primarily used for colorectal cancer screening, Exact Sciences has garnered a significant market presence.

The company's strengths lie in its commitment to delivering actionable results with high sensitivity and specificity, which resonates well with healthcare providers and patients alike. Furthermore, Exact Sciences has fostered beneficial partnerships with various healthcare institutions, further extending its reach and solidifying its competitive position in the market.

Abbott Laboratories operates within the US Clinical Laboratory Test Market with a comprehensive range of diagnostic products and services, particularly focusing on areas such as infectious diseases, autoimmune disorders, and cardiac health. The company is renowned for its extensive product lineup, which includes test kits and analyzers that are utilized in laboratories and point-of-care settings. Abbott's strengths come from its large-scale research capabilities and a robust supply chain that enables efficient product distribution across the US.

The company has made strategic moves through mergers and acquisitions to bolster its diagnostic portfolio, enhancing its capabilities and market position. In particular, Abbott’s advanced testing technologies, like molecular diagnostics and rapid testing solutions, demonstrate its unwavering commitment to innovation and meeting healthcare demands, allowing it to maintain a strong foothold in the competitive landscape of the clinical laboratory test market.

### **Key Companies in the US Clinical Laboratory Test Market Include**

- Exact Sciences
- [Abbott Laboratories](https://www.abbott.com/consumer/diagnostics.html)
- Thermo Fisher Scientific
- Cerner
- Quest Diagnostics
- PerkinElmer
- CSL Behring
- Hologic
- Genomic Health
- LabCorp
- BioReference Laboratories
- McKesson
- Roche Diagnostics
- Siemens Healthineers
- IDEXX Laboratories

## **US Clinical Laboratory Test Market Industry Developments**

The US Clinical Laboratory Test Market has witnessed significant developments in recent months. In September 2023, Quest Diagnostics announced the launch of a new genetic testing service aimed at improving the detection of hereditary cancers, highlighting the market's progressive shift towards personalized medicine. Furthermore, in August 2023, Abbott Laboratories reported a 10% growth in its diagnostics division, driven by increased demand for molecular testing and rapid COVID-19 testing solutions. Merger and acquisition activity remains robust, with Thermo Fisher Scientific completing its acquisition of PPD, a prominent contract research organization, in April 2023, which enhances its capabilities in clinical research services.

LabCorp also expanded its portfolio by acquiring a company focused on digital health services in June 2023, aligning with market trends emphasizing technology integration into diagnostics. Additionally, Hologic reported strong financial results in the second quarter of 2023, underscoring market resilience amid ongoing public health initiatives. Over the past few years, investments in **laboratory automation** and genomic testing have surged, reflecting a broader trend towards enhancing patient outcomes through advanced diagnostics in the competitive US market.

## **Clinical Laboratory Test Market Segmentation Insights**

### **Clinical Laboratory Test Market Type of Laboratory Outlook**

- Hospital-based
- Central/Independent
- Physician Office Laboratory
- Others

### **Clinical Laboratory Test Market Type of Test Outlook**

- CBC and Routine Blood Test
- Anatomic Pathology
- Molecular Test
- Immunology Test
- Drug Test
- Others

## Market Drivers

### Regulatory and Reimbursement Changes

Regulatory and reimbursement changes are shaping the landscape of the US Clinical Laboratory Test Market. Recent updates in healthcare policies and reimbursement models are influencing how laboratory tests are ordered, performed, and compensated. For instance, the implementation of value-based care models encourages laboratories to demonstrate the clinical utility of their tests. This shift may lead to increased scrutiny of laboratory services, compelling clinical laboratories to enhance their quality and efficiency. Additionally, changes in reimbursement rates for certain tests can impact laboratory revenues, prompting them to adapt their business strategies. As the regulatory environment continues to evolve, laboratories must remain agile to navigate these challenges effectively. The US Clinical Laboratory Test Market is thus likely to experience fluctuations as it responds to ongoing regulatory and reimbursement developments.

### Rising Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases in the United States is a primary driver of the US Clinical Laboratory Test Market. Conditions such as diabetes, cardiovascular diseases, and cancer are becoming more common, necessitating regular testing and monitoring. According to the Centers for Disease Control and Prevention, approximately 6 in 10 adults in the US have a chronic disease, which underscores the demand for laboratory tests. This trend is likely to continue, as the aging population further contributes to the rise in chronic conditions. Consequently, clinical laboratories are expanding their testing capabilities to meet the growing needs of healthcare providers and patients. The US Clinical Laboratory Test Market is thus positioned for growth as healthcare systems increasingly rely on laboratory tests for diagnosis, treatment, and management of these diseases.

### Advancements in Diagnostic Technologies

Technological advancements in diagnostic testing are significantly influencing the US Clinical Laboratory Test Market. Innovations such as molecular diagnostics, next-generation sequencing, and point-of-care testing are enhancing the accuracy and speed of laboratory results. For instance, the market for molecular diagnostics is projected to reach USD 11.5 billion by 2026, reflecting a compound annual growth rate of 10.5%. These advancements not only improve patient outcomes but also streamline laboratory operations, making them more efficient. As healthcare providers increasingly adopt these technologies, the demand for sophisticated laboratory tests is expected to rise. This trend indicates a robust future for the US Clinical Laboratory Test Market, as laboratories invest in cutting-edge technologies to remain competitive and meet evolving healthcare demands.

### Increased Focus on Preventive Healthcare

The growing emphasis on preventive healthcare is driving the US Clinical Laboratory Test Market. As healthcare systems shift from reactive to proactive approaches, there is a heightened demand for routine screenings and diagnostic tests. Preventive measures, such as early detection of diseases, are crucial in reducing healthcare costs and improving patient outcomes. The US Preventive Services Task Force recommends various screenings, which has led to an increase in laboratory test utilization. This trend is likely to continue, as both patients and providers recognize the value of preventive care. Consequently, clinical laboratories are expanding their test offerings to include a wider range of preventive screenings, thereby enhancing their role in the healthcare continuum. The US Clinical Laboratory Test Market stands to benefit from this shift towards preventive healthcare, as it aligns with broader public health goals.

### Growing Demand for Home Testing Solutions

The rising demand for home testing solutions is emerging as a significant driver of the US Clinical Laboratory Test Market. With advancements in technology, patients are increasingly seeking convenient and accessible testing options that can be performed in the comfort of their homes. This trend is reflected in the growing popularity of at-home testing kits for various conditions, including diabetes, cholesterol levels, and infectious diseases. The convenience of home testing not only empowers patients but also alleviates pressure on clinical laboratories. As a result, laboratories are adapting their services to accommodate this shift, offering more home testing options and ensuring accurate results. The US Clinical Laboratory Test Market is poised for growth as it embraces this trend, catering to the evolving preferences of patients and healthcare providers.

## Future Outlook

The US [Clinical Laboratory Test Market](https://www.marketresearchfuture.com/reports/clinical-laboratory-test-market-1649) is projected to grow at a 15.8% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for diagnostics, and a growing aging population.

**New opportunities:**

- Expansion of telehealth services for remote diagnostics Development of personalized medicine testing kits Investment in AI-driven laboratory automation solutions

By 2035, the market is expected to be robust, driven by innovation and increased healthcare demands.

## Segment Insights

### By Type of Laboratories: Rigid (Largest) vs. Flexible (Fastest-Growing)

In the US clinical laboratory-test market, the Rigid segment holds a significant share, dominating the landscape with its established presence and operational efficiency. It benefits from long-standing relationships with healthcare providers and a reputation for reliability, which fortifies its position. Conversely, the Flexible segment is witnessing an upward trend, capturing the interest of innovative labs looking to adapt to evolving patient needs, thus contributing to a dynamic market distribution.

Growth trends indicate a notable shift towards Flexible laboratory setups, driven by the need for adaptability in testing procedures and patient-centric care models. The push for personalized medicine and rapid diagnostic testing is further accelerating this trend. As laboratories increasingly prioritize versatility and responsiveness, the Flexible segment is expected to continue as the fastest-growing sector, attracting investments and technology advancements that enhance efficiency and operational effectiveness.

Laboratories: Rigid (Dominant) vs. Flexible (Emerging)

The Rigid laboratories are characterized by their fixed structures, standardized processes, and reliable output, making them preferred choices among traditional healthcare institutions. They have established protocols and a reputation for dependability, supporting a wide range of diagnostic tests and procedures. In contrast, Flexible laboratories represent a rapidly emerging trend that focuses on adaptability and real-time responses to testing demands. These labs implement modular designs and innovative technologies, addressing the growing need for customized testing solutions. While Rigid laboratories dominate the market due to their stability, Flexible laboratories are capturing attention for their potential to innovate and improve service delivery, positioning them as formidable contenders in the evolving landscape of laboratory diagnostics.

### By Type of Tests: Complete Blood Count (CBC) (Largest) vs. HbA1c Tests (Fastest-Growing)

In the US clinical laboratory-test market, Complete Blood Count (CBC) tests hold the largest market share among the various testing types, demonstrating their widespread usage for comprehensive health assessments. Following CBC, the HbA1c Tests are rapidly gaining traction due to their importance in diabetes management, contributing to a notable rise in their adoption across laboratories.

The growth trends for laboratory tests reveal a shift towards preventive healthcare, with tests like the HbA1c Tests becoming increasingly preferred as the awareness of chronic conditions rises. Innovations in laboratory technology and greater emphasis on routine health check-ups are driving the expansion of this segment. This trend is likely to continue as healthcare providers prioritize comprehensive testing to ensure timely interventions.

Complete Blood Count (CBC) (Dominant) vs. HbA1c Tests (Emerging)

Complete Blood Count (CBC) tests are viewed as the cornerstone of diagnostic testing, providing critical information on a patient's overall health. These tests are commonly used to identify various conditions, including anemia, infections, and many other disorders. With an established market position, CBC tests benefit from high demand due to their accuracy and reliability. Conversely, HbA1c Tests, previously less prominent, are emerging swiftly as an essential tool for monitoring long-term glucose control in diabetic patients. Their growing significance is supported by rising diabetes prevalence and advancements in testing methodologies, making them more accessible and efficient. This dual dynamic showcases how established tests continue to dominate while new entrants like HbA1c are rapidly reshaping the landscape.

### By Application: Hematology (Largest) vs. Immunology/Serology (Fastest-Growing)

The application segment within the US clinical laboratory-test market showcases a diverse distribution of market shares among various values. Hematology stands as the largest segment, driven by an increasing demand for blood testing and analysis in clinical settings. In contrast, immunology/serology is emerging as a crucial player, benefitting from advancements in disease detection and monitoring techniques, appealing to a growing patient base. Growth trends indicate a robust evolution within this market segment, fueled by technological innovations and an increasing emphasis on preventive healthcare. Rising prevalence of infectious diseases and a growing geriatric population further boost the need for comprehensive laboratory testing solutions. Moreover, investments in research and development propel the growth of immunology/serology, solidifying its position as the fastest-growing area, thereby reflecting the overall dynamic nature of the US clinical laboratory-test market.

Hematology: Dominant vs. Immunology/Serology: Emerging

Hematology, as the dominant application segment, plays a critical role in the US clinical laboratory-test market due to its extensive use in diagnosing blood-related disorders, including anemia and clotting disorders. This segment is well-established, with a wealth of technologies ranging from automated analyzers to advanced microscopy techniques, facilitating rapid test results and high accuracy. Conversely, immunology/serology represents the emerging portion of the market, driven by its essential contributions to understanding immune responses and infectious diseases. Innovations in biomarker identification and assay development are propelling this segment forward, showcasing its potential for exceptional growth driven by an increased focus on personalized medicine and disease prevention strategies.

## Regional Market Share Analysis

### North America : Market Leader in Testing

The North American clinical laboratory test market is the largest globally, driven by advanced healthcare infrastructure, high demand for diagnostic testing, and supportive regulatory frameworks. The U.S. holds approximately 70% of the market share, with Canada following at around 15%. The increasing prevalence of chronic diseases and the aging population are significant growth drivers, alongside innovations in laboratory technologies and testing methodologies. The competitive landscape is characterized by major players such as Quest Diagnostics, Laboratory Corporation of America, and Mayo Clinic Laboratories. These companies dominate the market with extensive service offerings and advanced testing capabilities. The presence of key players fosters innovation and enhances service delivery, ensuring that North America remains at the forefront of clinical laboratory testing advancements.

### Europe : Emerging Market Dynamics

Europe is witnessing a significant transformation in the clinical laboratory test market, driven by increasing healthcare expenditure and a growing emphasis on preventive healthcare. The region holds approximately 20% of the global market share, with Germany and the UK being the largest contributors. Regulatory support for innovative diagnostic solutions and the rising prevalence of infectious diseases are key factors propelling market growth in this region. Leading countries in Europe, such as Germany, France, and the UK, are home to several prominent players, including Roche and Siemens Healthineers. The competitive landscape is evolving, with a focus on technological advancements and partnerships to enhance testing capabilities. The presence of established laboratories and research institutions further strengthens the market, fostering innovation and improving patient outcomes.

### Asia-Pacific : Rapid Growth and Innovation

The Asia-Pacific region is rapidly emerging as a powerhouse in the clinical laboratory test market, driven by increasing healthcare investments and a growing population. Countries like China and India are leading this growth, collectively holding around 10% of the global market share. The rising prevalence of chronic diseases and the demand for advanced diagnostic solutions are key growth drivers, supported by government initiatives to improve healthcare access and quality. China and India are at the forefront of this market expansion, with significant investments in healthcare infrastructure and technology. The competitive landscape features both local and international players, including Thermo Fisher Scientific and Genomic Health. The region's focus on innovation and research is fostering a dynamic environment for clinical laboratory testing, enhancing service delivery and patient care.

### Middle East and Africa : Untapped Market Potential

The Middle East and Africa region presents untapped potential in the clinical laboratory test market, driven by increasing healthcare investments and a growing focus on disease prevention. The market share in this region is approximately 5%, with countries like South Africa and the UAE leading the way. The rising burden of infectious diseases and the need for improved healthcare infrastructure are significant growth catalysts, supported by government initiatives to enhance healthcare services. South Africa and the UAE are key players in this market, with a growing number of private laboratories and diagnostic centers. The competitive landscape is evolving, with both local and international companies striving to establish a foothold. The presence of key players and ongoing investments in healthcare technology are expected to drive market growth, improving access to quality diagnostic services across the region.

## Competitive Benchmarking

The clinical laboratory-test market in the US is characterized by a dynamic competitive landscape, driven by technological advancements, increasing demand for diagnostic testing, and a growing emphasis on personalized medicine. Major players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Thermo Fisher Scientific (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Abbott Laboratories (US) focuses on expanding its diagnostic portfolio through continuous innovation, while Roche Diagnostics (CH) emphasizes its strong R&D capabilities to develop cutting-edge diagnostic solutions. Thermo Fisher Scientific (US) is strategically positioned through its comprehensive product offerings and robust supply chain, which collectively shape a competitive environment that is increasingly reliant on technological differentiation and operational efficiency. Key business tactics within this market include localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. The competitive structure appears moderately fragmented, with several key players exerting significant influence. This fragmentation allows for a diverse range of products and services, fostering innovation while also creating challenges in maintaining market share amidst intense competition. In October 2025, Abbott Laboratories (US) announced the launch of its new rapid diagnostic test for infectious diseases, which is expected to significantly reduce turnaround times for results. This strategic move not only enhances Abbott's product portfolio but also positions the company to capture a larger share of the growing demand for rapid testing solutions. The introduction of this test reflects a broader trend towards speed and efficiency in diagnostics, which is becoming increasingly critical in the current healthcare landscape. In September 2025, Roche Diagnostics (CH) unveiled a partnership with a leading AI technology firm to integrate artificial intelligence into its diagnostic platforms. This collaboration aims to enhance the accuracy and efficiency of diagnostic testing, indicating Roche's commitment to leveraging technology to improve patient outcomes. The integration of AI is likely to set Roche apart from competitors, as it aligns with the industry's shift towards data-driven decision-making in healthcare. In August 2025, Thermo Fisher Scientific (US) completed the acquisition of a biotechnology firm specializing in molecular diagnostics. This acquisition is anticipated to bolster Thermo Fisher's capabilities in the molecular testing segment, allowing for a more comprehensive suite of diagnostic solutions. The strategic importance of this move lies in Thermo Fisher's ability to expand its market reach and enhance its competitive edge through a broader product offering. As of November 2025, current competitive trends in the clinical laboratory-test market include a pronounced focus on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological innovation, reliability in supply chains, and the ability to deliver personalized healthcare solutions. This shift underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive advantage.

## Recent News & Developments

The US Clinical Laboratory Test Market has witnessed significant developments in recent months. In September 2023, Quest Diagnostics announced the launch of a new genetic testing service aimed at improving the detection of hereditary cancers, highlighting the market's progressive shift towards personalized medicine. Furthermore, in August 2023, Abbott Laboratories reported a 10% growth in its diagnostics division, driven by increased demand for molecular testing and rapid COVID-19 testing solutions. Merger and acquisition activity remains robust, with Thermo Fisher Scientific completing its acquisition of PPD, a prominent contract research organization, in April 2023, which enhances its capabilities in clinical research services.

LabCorp also expanded its portfolio by acquiring a company focused on digital health services in June 2023, aligning with market trends emphasizing technology integration into diagnostics. Additionally, Hologic reported strong financial results in the second quarter of 2023, underscoring market resilience amid ongoing public health initiatives. Over the past few years, investments in **laboratory automation** and genomic testing have surged, reflecting a broader trend towards enhancing patient outcomes through advanced diagnostics in the competitive US market.

## Report Scope

| MARKET SIZE 2024 | 1.207(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.397(USD Billion) |
| MARKET SIZE 2035 | 6.06(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 15.8% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Quest Diagnostics (US), Laboratory Corporation of America (US), Mayo Clinic Laboratories (US), BioReference Laboratories (US), ARUP Laboratories (US), Sonic Healthcare (AU), Genomic Health (US), Exact Sciences (US), Thermo Fisher Scientific (US) |
| Segments Covered | Types of Laboratory, Types of Test |
| Key Market Opportunities | Integration of advanced diagnostic technologies enhances efficiency in the US Clinical Laboratory Test Market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the US Clinical Laboratory Test Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the US clinical laboratory-test market?**
A: The market valuation was $30.5 Billion in 2024.

**Q: What is the projected market size for the US clinical laboratory-test market by 2035?**
A: The market is expected to reach $78.0 Billion by 2035.

**Q: What is the expected CAGR for the US clinical laboratory-test market during 2025 - 2035?**
A: The expected CAGR is 8.91% during the forecast period.

**Q: Which companies are the key players in the US clinical laboratory-test market?**
A: Key players include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific.

**Q: What are the two main types of laboratories in the US clinical laboratory-test market?**
A: The two main types are rigid laboratories, valued at $12.2 Billion, and flexible laboratories, valued at $18.3 Billion.

**Q: What is the market size for the Complete Blood Count (CBC) test in the US clinical laboratory-test market?**
A: The market size for the CBC test was $3.5 Billion in 2024 and is projected to reach $8.5 Billion.

**Q: How does the market for Immunology/Serology tests compare to other applications?**
A: The Immunology/Serology application is valued at $7.0 Billion and is expected to grow to $18.0 Billion.

**Q: What is the valuation of the Toxicology segment in the US clinical laboratory-test market?**
A: The Toxicology segment was valued at $4.0 Billion in 2024 and is projected to reach $10.0 Billion.

**Q: What is the market size for the Basic Metabolic Panel (BMP) test?**
A: The BMP test was valued at $4.0 Billion in 2024 and is expected to grow to $10.0 Billion.

**Q: What is the projected growth for the Hematology application in the US clinical laboratory-test market?**
A: The Hematology application was valued at $5.0 Billion in 2024 and is projected to reach $12.0 Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-clinical-laboratory-test-market-12793*